FDC Limited (BOM:531599)
India · Delayed Price · Currency is INR | Market Cap | 62.62B -16.3% |
| Revenue (ttm) | 21.71B +3.0% |
| Net Income | 2.81B +5.5% |
| EPS | 17.29 +5.5% |
| Shares Out | 162.81M |
| PE Ratio | 22.24 |
| Forward PE | n/a |
| Dividend | 5.00 (1.30%) |
| Ex-Dividend Date | Feb 11, 2026 |
| Volume | 5,183 |
| Open | 392.45 |
| Previous Close | 384.70 |
| Day's Range | 382.00 - 392.45 |
| 52-Week Range | 314.75 - 528.30 |
| Beta | 0.18 |
| Analysts | Strong Buy |
| Price Target | 350.00 (-9.0%) |
| Earnings Date | May 27, 2026 |
About FDC Limited
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutio... [Read more]
Financial Performance
In fiscal year 2026, FDC Limited's revenue was 21.71 billion, an increase of 2.98% compared to the previous year's 21.08 billion. Earnings were 2.81 billion, an increase of 5.49%.
Financial StatementsNews
FDC reports Rs 585 crore revenue in Q4 FY26 with 18.9% growth
FDC Limited has announced its financial results for the fourth quarter and the fiscal year ended March 31, 2026. The company reported a revenue from operations of ₹585 crores for…
FDC reports 18.9% revenue growth in Q4 FY26, driven by strong export performance
FDC Limited has announced its financial results for the fourth quarter and year ended March 31, 2026, showcasing significant growth across its business segments. The company's consolidated revenue fro...
FDC Limited receives US FDA ANDA approval for Cefixime Oral Suspension — opens new revenue line in US antibiotic market
FDC Limited has received Abbreviated New Drug Application approval from the United States Food and Drug Administration for Cefixime for Oral Suspension, the company disclosed on May 18, 2026. Cefixime...
FDC reconstitutes board committees and appoints Mohan Chandavarkar as chairman
FDC Limited has announced a reconstitution of its board committees, effective from 1 April 2026. The changes include updates to the Audit Committee, Nomination and Remuneration Committee, and Corporat...
FDC receives ANDA approval from U.S. FDA for Pilocarpine Hydrochloride Ophthalmic Solution USP
FDC Limited, a leading Indian pharmaceutical company, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA)...
FDC shares drop over 3% as Q4 EBITDA falls 4.2% YoY to Rs 54 crore, net profit down 16.4% YoY
Shares of FDC Ltd dropped more than 3% following the release of its fourth-quarter financial results, which showed a mixed performance. Despite a moderate increase in revenue, profitability declined, ...
FDC receives US FDA approval for Cefixime 400 mg tablets
FDC Limited has recently informed exchanges that the company has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Cefixime 4...
FDC shares surge 11%, leading gains in BSE Healthcare index
Shares of FDC Limited surged by 11.22% today, reaching ₹642.95, making it one of the top performers in the BSE Healthcare Index. The index itself was up 1.0%, with other top gainers including Hikal Ch...